Back

Comparative effectiveness of sleeve gastrectomy and one-anastomosis gastric bypass on cardiovascular disease risk

31 August 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Obesity (2) Obesity ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Danial Molavi zadeh

Shahid Beheshti University of Medical Sciences, Tehran (Iran (Islamic Republic of))

5 More presentations in this session

Presentation thumbnail
Cardiovascular risk factors associated with normal weight obesity among Hispanic adults
Doctor A. Villarreal Rizzo (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Different response of plaque regression under achieving LDL-C <1.8 mmol/L in non-obese and obese diabetic patients with coronary artery disease: a sub-analysis from the OPTIMAL randomized study
Doctor A. Salib (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Associations of visceral adipose tissue with ASCVD across BMI categories
Doctor U. Makhmudova (Berlin, DE) Doctor A. Sannino (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Impact of obesity on the association between salt intake and blood pressure in adults with hypertension: findings from cross-sectional and longitudinal analyses
Assistant Professor T. Adachi (Nagoya, JP)
Abstract Slides Video
Presentation thumbnail
Obesity duration and the risk of myocardial infarction: insights from the National Institutes of Health All of Us Research Program
Doctor S. Sidhu (New York, US)
Abstract Slides Video

Access the full session

Session thumbnail
Obesity (2)

The Event

Event poster

ESC Congress 2025

31 August 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of laparoscopic sleeve gastrectomy on cardiac functions assessed by cardiac magnetic resonance, metabolic parameters, quality of life measures, and biomarkers
thumbnail
Congress Session
Challenges of managing obesity in cardiovascular disease
thumbnail
Congress Presentation
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources